聚合物製药 CDMO 市场规模、份额、成长分析，按服务、按供应商、按最终用户、按地区 - 2025 年至 2032 年行业预测

预计2023年全球大分子药物CDMO市场规模将达到118.6亿美元，并将从2024年的128.8亿美元成长到2032年的249.2亿美元，预测期内（2025-2032年）的复合年增长率为8.6%。

由于 FDA 对大分子药物的核准不断增加、感染疾病激增以及对创新疗法的需求不断增长，大分子合约开发和受託製造厂商(CDMO) 市场正在迅速发展。製药和生物技术公司对先进技术的投资进一步加速了与 CDMO 的合作，尤其是在 COVID-19 之后，凸显了生技药品在开发疫苗和治疗方法中的重要性。这次疫情加速了疫苗和单株抗体生产新技术的采用，并凸显了美国本土合约服务的需求。然而，聚合物开发的复杂性对可负担性、速度和功效带来了挑战。为了稳定这些复杂的治疗药物，封装和缓衝技术等创新解决方案应运而生，确保在这个竞争激烈的市场中拥有更强大的供应链。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

聚合物药物 CDMO 市场规模（按服务）

• 市场概况
• 契约製造
  • 临床
  • 商业的
• 合约开发
  • 细胞株开发
  • 製程开发

聚合物药物 CDMO 市场规模（依供应商）

• 市场概况
• 哺乳类
• 微生物
• 其他的

聚合物药物 CDMO 市场规模（按最终用户划分）

• 市场概况
• 生技公司
• 执行长
• 其他的

聚合物药物CDMO市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Lonza Group（Switzerland）
• Thermo Fisher Scientific（United States）
• Catalent（United States）
• WuXi Biologics（China）
• Samsung Biologics（South Korea）
• Siegfried Holding AG（Switzerland）
• AGC Biologics（United States）
• Avid Bioservices（United States）
• Boehringer Ingelheim BioXcellence（Germany）
• Fujifilm Diosynth Biotechnologies（United States）
• Rentschler Biopharma SE（Germany）
• Recipharm AB（Sweden）
• Syngene International（India）
• KBI Biopharma（United States）
• JHL Biotech（Taiwan）
• Emergent BioSolutions（United States）
• Wuxi AppTec（China）
• BioVectra（Canada）
• Abzena（United Kingdom）

结论和建议

Global Large Molecule Drug Substance CDMO Market size was valued at USD 11.86 billion in 2023 and is poised to grow from USD 12.88 billion in 2024 to USD 24.92 billion by 2032, growing at a CAGR of 8.6% during the forecast period (2025-2032).

The market for large molecule drug substance Contract Development and Manufacturing Organizations (CDMOs) is rapidly evolving, driven by increasing FDA approvals for large molecules, a surge in infectious diseases, and heightened demand for innovative therapeutics. Investment from pharmaceutical and biotech firms in advanced technologies has further spurred partnerships with CDMOs, especially post-COVID-19, highlighting the importance of biologics in developing vaccines and treatments. The pandemic accelerated the adoption of new technologies for vaccine and monoclonal antibody production, while emphasizing the necessity for regional, US-based contract services. However, the intricate nature of large molecule development challenges affordability, speed, and effectiveness. Innovative solutions, such as encapsulation and buffering techniques, have emerged to stabilize these complex therapeutic agents, ensuring a stronger supply chain in this competitive market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Large Molecule Drug Substance Cdmo market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Large Molecule Drug Substance CDMO Market Segmental Analysis

Global Large Molecule Drug Substance CDMO Market is segmented by Service, Source, End-user and region. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Source, the market is segmented into Mammalian, Microbial and Others. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Large Molecule Drug Substance CDMO Market

The global market for Large Molecule Drug Substance CDMOs is principally driven by the surge in research and development of biologics and biosimilars, particularly since the pandemic. Companies have significantly invested in the creation of these substances, and currently, approximately fifty percent of prospective therapeutic candidates in the discovery phase encompass biologics, including peptides, proteins, and monoclonal antibodies. This heightened focus on innovative biologics has led to a robust pipeline of new products, spurring further investment from biopharmaceutical firms. Accordingly, these factors collectively fuel the growth of the large molecule drug substance CDMO sector in the global marketplace.

Restraints in the Global Large Molecule Drug Substance CDMO Market

The Global Large Molecule Drug Substance CDMO market faces several restraints, primarily stemming from stringent regulatory requirements and the inherent complexity of analytically characterizing biologics. These large molecules present unique challenges, as comprehensive characterization is essential to assess their stability, purity, and functionality across various applications. Effective structural validation requires integrating multiple low- and high-resolution techniques, which adds to the intricacies. Furthermore, the recombinant synthesis of these large molecules often leads to various post-translational modifications (PTMs), complicating the characterization process. Nevertheless, an increase in research and development investments is driving growth within the large molecule drug substance CDMO market.

Market Trends of the Global Large Molecule Drug Substance CDMO Market

The Global Large Molecule Drug Substance CDMO market is witnessing significant transformation driven by the rapid growth of large molecule biopharmaceuticals and the unique challenges they present in commercial-scale manufacturing. Unlike small molecules, these biologics require distinct batch processes, often influencing production capacities. The rise of targeted therapies, such as antibody-drug conjugates, is enhancing focus in oncology treatments. Smaller firms are prevalent, often lacking the infrastructure for effective scale-up and technology transfer. Consequently, established CDMOs must innovate their operations and invest in advanced technologies to meet the complex demands of tailored therapies, manage high-potency APIs, and navigate stringent regulatory landscapes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Large Molecule Drug Substance CDMO Market Size by Service & CAGR (2025-2032)

• Market Overview
• Contract Manufacturing
  • Clinical
  • Commercial
• Contract Development
  • Cell Line Development
  • Process Development

Global Large Molecule Drug Substance CDMO Market Size by Source & CAGR (2025-2032)

• Market Overview
• Mammalian
• Microbial
• Others

Global Large Molecule Drug Substance CDMO Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Biotech Companies
• CRO
• Others

Global Large Molecule Drug Substance CDMO Market Size & CAGR (2025-2032)

• North America (Service, Source, End-user)
  • US
  • Canada
• Europe (Service, Source, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Source, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Source, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Source, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avid Bioservices (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim BioXcellence (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rentschler Biopharma SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JHL Biotech (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVectra (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations